All In Biotech

Drug Trial Radar · NCT04416581

Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy

A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,320 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,320

Planned (sponsor's estimate)

Start

May 12, 2021

Primary completion

Dec 31, 2027

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Duk-Woo Park, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known cardiac and vascular disease receiving chronic use of antithrombotic drugs (either antiplatelets, OAC, and its combinations) who are at high GI bleeding risk. The primary hypothesis is that P-CAB (experimental arm) would non-inferior to PPI (standard arm) with respect to the rate of the primary composite end point of GI events at 12 months after randomization.

Conditions

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention
  • Acute Coronary Syndrome
  • Myocardial Infarction

Interventions

  • PPIDrug

    rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.

  • P-CAB 50Drug

    tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time from randomization to the first occurrence of a composite endpoint of upper GI clinical events, including during the treatment periodTime frame: 12 months

Locations

45 sites in 1 country. Site status is shown where the registry gives one.

  • Hallym University Sacred Heart Hospital

    Anyang, South Korea · Recruiting

  • Bucheon Sejong Hospital

    Bucheon-si, South Korea · Recruiting

  • Kosin University Gospel Hospital

    Busan, South Korea · Recruiting

  • Gyeongsang National University Changwon Hospital

    Changwon, South Korea · Withdrawn

  • Sungkyunkwan University Samsung Changwon Hospital

    Changwon, South Korea · Withdrawn

  • Dankook University Hospital

    Cheonan, South Korea · Withdrawn

  • Chungbuk National University Hospital

    Cheonju, South Korea · Recruiting

  • Gangwon National Univ. Hospital

    Chuncheon, South Korea · Not yet recruiting

  • Hallym University Chuncheon Sacred Heart Hospital

    Chuncheon, South Korea · Not yet recruiting

  • Keimyung University Dongsan Medical Center

    Daegu, South Korea · Recruiting

  • Yeungnam University Medical Center

    Daegu, South Korea · Withdrawn

  • Chungnam National University Hospital

    Daejeon, South Korea · Recruiting

  • Gangneung Asan Hospital

    Gangneung, South Korea · Recruiting

  • Hanyang University Guri Hospital

    Guri-si, South Korea · Recruiting

  • Chonnam National University Hospital

    Gwangju, South Korea · Recruiting

  • Hallym University Dongtan Sacred Heart Hospital

    Hwaseong-si, South Korea · Recruiting

  • Inje University Ilsan Paik Hospital

    Ilsan, South Korea · Recruiting

  • Jeonbuk National University Hospital

    Jeonju, South Korea · Withdrawn

  • Kwangju Christian Hospital

    Kwangju, South Korea · Withdrawn

  • Dong-A Medical Center

    Pusan, South Korea · Recruiting

  • Inje University Pusan Paik Hospital

    Pusan, South Korea · Recruiting

  • Pusan National University Hospital

    Pusan, South Korea · Recruiting

  • Chungnam National University Sejong Hospital

    Sejong, South Korea · Recruiting

  • Bundang CHA Hospital

    Seongnam, South Korea · Recruiting

  • Seoul university Bundang hospital

    Seongnam-si, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Chung-Ang University Hospital

    Seoul, South Korea · Recruiting

  • Ewha Womans University Medical Center

    Seoul, South Korea · Withdrawn

  • Hallym University Kangnam Sacred Heart Hospital

    Seoul, South Korea · Recruiting

  • Hanyang University Seoul Hospital

    Seoul, South Korea · Recruiting

  • Kangbuk Samsung Hospital

    Seoul, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Recruiting

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea · Recruiting

  • Kyung Hee University Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • SNU Boramae Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic Univ. of Korea Eunpyeong St. Mary's hospital

    Seoul, South Korea · Recruiting

  • The Catholic Univ. of Korea Seoul St. Mary's hospital

    Seoul, South Korea · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.